Clinigen Share Discussion Threads

[firtashia] 11/11/2014 14:07

Aphrodites, post 9 - a really good call. Good stuff.

[hutch_pod] 10/11/2014 22:34

I dare say the broker targets are looking plausible again

[gucci] 09/11/2014 12:56

Thanks hutch_pod

[hutch_pod] 08/11/2014 23:09

Thanks to clausentum for flagging. Nice tip.

[gucci] 08/11/2014 22:27

Where did you see that clausentum?

[clausentum] 08/11/2014 20:32

Recommended by Jim Slater, so likely to soar on Monday.

He wrote that he bought £1.5M of shares at 470p in October, so that could explain the MMs activity at that time.

[hutch_pod] 05/11/2014 11:28

Phew. Back to 500. Apologies for the interlude perhaps.

[hutch_pod] 04/11/2014 17:43

Could be 500s tomorrow. IC say sector PE average is 21, so at 2015 EPS of 26ish, that would give 546.

[gucci] 04/11/2014 00:32

Heading back to 650p

[hutch_pod] 03/11/2014 13:36

mini breakout. Good to see 480 touched!!

[mike740] 10/10/2014 10:35

Up we go onto the positive side, excelent.

[nhb001] 08/10/2014 18:47

Hello Aphrodites, what trading patters are you referring to? I don't have Level 2 access.

[aphrodites] 08/10/2014 16:35

Someone has an insatiable appetite for stock and the MM's are struggling to get hold of any. They are keeping a lid on this and I would not be surprised to see the price go a lot, lot higher than where we are today.

I would not be surprised to see it hit £5.50 in the next 14 days!!

DO NOT SELL.

[rjd123] 02/10/2014 16:33

Seeing a bit of a sell off today.

[johnv] 02/10/2014 12:21

Topped up as well

[aphrodites] 02/10/2014 11:02

Nothing like hanging out a bit of bait for the MM's to take hook, line and sinker and get the price down to buy cheap stock.

Many thanks boys!

[aphrodites] 02/10/2014 08:12

Clearly not a lot of followers of this stock on ADVFN. However, I think it might be worth commenting to those that do follow it that there is clearly a big buyer in the market and efforts are being made nearly every day to shake out weak holders and to suppress the price.

The liquidity of the stock is very poor and the price can jump 20p for no apparent reason. It can be marked down also!

I think it might be worth buying a few as the trading pattern indicates something is going on behind the scenes.

Could there be a predator sniffing around???? If so it will have to pay at least £7 plus!!!!!!!!!!

[hutch_pod] 01/10/2014 15:16

Guess 500p is going to take a little bit longer

[hutch_pod] 01/10/2014 15:13

Moneyweek/penny sleuth tip

hxxp://moneyweek.com/penny-sleuth-clinigen-investing-in-pharmaceuticals/

[whymps2] 29/9/2014 15:38

Clinigen : Receives FDA’s First Ever Drug Shortage Assistance Award
09/29/2014 | 02:29am US/Eastern
Recommend:
0

Clinigen Group plc (‘ClinigenR17; or the ‘Group’, AIM:CLIN) the global specialty pharmaceutical company, today announces that it has received the first Drug Shortage Assistance Award from the US Food and Drug Administration (FDA) in recognition of its contribution in addressing a US shortage of Foscavir® (foscarnet sodium) injection.

Clinigen’s efforts related to the US shortage included making Foscavir® available on a named patient basis whilst acquiring the new drug application and submitting post-approval supplements to restart manufacturing with acceptable compliance records. These actions by Clinigen resolved a critical drug shortage affecting patients.

This award also recognizes companies for their commitment to public health, as well as to quality manufacturing and is the first time the award has been made by the FDA.

Peter George, Chief Executive Officer, Clinigen Group, said: “To be the recipient of this new award from the FDA is a great honor and absolutely reflects Clinigen’s mission to ensure that the right drug reaches the right patient at the right time. Since acquiring Foscavir® from AstraZeneca in 2010, we have worked hard to expand the indications and markets for the drug to increase the number of patients who can benefit. It is a real compliment that the FDA is committed to working with companies, like Clinigen, to prevent and mitigate drug shortages.”

Drug shortages pose a substantial public health threat, delaying, and in some cases even denying, critically needed care for patients. Working with drug manufacturers, the FDA helped prevent over 280 drug shortages in 2012 and 170 in 2013. There were 44 new drug shortages in 2013, down from 117 new drug shortages in 2012. Two key prevention strategies have helped drive this significant decrease in new shortages: 1) early notification and 2) a focus on quality manufacturing.

[cestnous] 26/9/2014 09:19

I.C. today

Clinigen still clinical
When drugs fail to obtain licenses or are pulled off the market, clinicians can miss out on vital elements of medical treatment. Clinigen (CLIN) fills this gap, acquiring, revitalising and then distributing the drugs. This focus helped it record a 20 per cent rise in underlying cash profits for the year to June.
Sales at Clinigen’s key clinical trials supply division fell 5 per cent to £84m, reflecting a one-off bump in antiviral sales in 2013. But it did record a 45 per cent increase in supply requests, as the company widened its market share, so sales should rebound. It also signed an exclusive supply agreement for an oncology drug with an international pharmaceutical company.
Clinigen’s specialty pharmaceuticals division grew its product range by acquiring Savene and Ethyol, two oncology support products. That should help to compensate for slowing sales of Foscavir now its revitalisation is largely complete. Clinigen also convinced European regulators to lift the suspension order on its injectable antibiotic Vibativ, which combats hospital-acquired pneumonia.
Meanwhile, sales surged by more than half at its global access programs segment, as it shipped 58,000 drug units – up 87 per cent – to over 75 countries. The division also added AstraZeneca (AZN) and Eisai to its client list.
Broker Numis Securities expects pre-tax profit of £29m, giving EPS of 26.1p, rising to £35m and 31.6p in 2015-16.
C Clinigen’s growing product range and diversified business model should serve investors well. Its shares trade at 18 times forecast earnings – a discount to the sector average of 21. We reiterate our buy tip. TM

[chrisgail] 24/9/2014 18:49

A very solid set of results present share price values the company undemandingly, plenty of share price appreciation to go, I remain a longterm holder.

[hutch_pod] 24/9/2014 15:37

Finally read most of the RNS. Strong set of numbers, and the underlying EBITDA or EPS growth of 19.8% / 22% looks entirely repeatable.

Like the fact that despite most of the business being abroad, FX is only briefly mentioned in regards to revenue.

Interesting comment from Proactive:

"Peter George, the chief executive of Clinigen Group (LON:CLIN), says the company is hoping to leave its mark on the Asian, South American and possibly African markets. He says that will mean direct contact with patients and customers rather than going through third parties. George’s comments accompany the group’s preliminary results, which showed like-for-like revenues up 7.5% and underlying earnings up almost 20%."

[...]

Market seems unexcited but hopefully 2015 will continue the pattern of consistent delivery.

[mechanical trader] 24/9/2014 10:10

24 Sep 2014 Clinigen Group CLIN Oriel Securities Buy 463.50 456.00 650.00 650.00 Reiterates

SP TARGET 650p.

[mechanical trader] 24/9/2014 09:33

24 Sep 2014 Clinigen Group CLIN Numis Buy 465.50 456.00 650.00 650.00 Reiterates

650p share price TARGET